Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIn the STEP 1 clinical trial — 68 weeks, 2.4mg semaglutide — participants lost an average of around 15% of their body weight, published in the New England Journal of Medicine. For someone weighing 100kg at the start, that translates to roughly 15kg. Results vary person to person, and how much weight you can expect to lose on Wegovy depends on your starting weight, your lifestyle alongside the medicine, how long you take it, and whether you reach and tolerate the full maintenance dose. Wegovy is a prescription-only medicine; a clinician, not an online form, decides whether it is suitable for you and at what dose to begin.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The headline figure from STEP 1 is around 15% average body-weight reduction over 68 weeks at the 2.4mg maintenance dose. That is the number most cited by the NHS, NICE and prescribers when patients ask how much weight can you expect to lose on Wegovy, and it is the right place to start.
A few things worth understanding behind that number. First, it is an average across a large trial population, some participants lost considerably more, others less. Second, it reflects people who reached and stayed on the 2.4mg dose alongside a reduced-calorie diet and increased activity. Third, weight loss tends to build gradually: the titration schedule that starts at 0.25mg and steps up over several months is designed to help your body adjust, not to produce quick early results. If you are curious about what the first few weeks and months might realistically look like, our page on monthly weight loss on Wegovy covers that in detail.
The newer 7.2mg single-dose pen, approved by the MHRA in April 2026, showed around 20.7% average weight loss over 72 weeks in trials, meaningfully higher than 2.4mg, though it requires titrating through the existing dose steps first under prescriber guidance. If you want a realistic sense of how much weight you should expect to lose on Wegovy, our dedicated page works through the evidence and individual variables in detail. More on Wegovy's overall weight-loss range can help set realistic expectations before you start.
UK private Wegovy treatment is priced per pen or per monthly supply, and the figure varies by dose and provider. Since Eli Lilly's list-price increase in September 2025, the broader market for weight-loss injections has seen prices rise, with typical private costs reported in the range of roughly £149 to £375 a month depending on dose and service. Those figures are hedged, your actual cost at any provider depends on which dose you are on and what the quoted price actually includes.
That last point matters more than people realise. A low headline price sometimes covers the pen only. Consultation fees, the prescription itself, delivery charges and any aftercare calls can all sit outside it, added at checkout or charged when you need support. Understanding the full cost of treatment, not just the opening number, is the sensible comparison to make. Our Wegovy price guide sets out what drives cost variation clearly.
At nume, one transparent price covers everything: consultation, prescription, the medicine, free next-working-day delivery, and 7-day aftercare. We do not run subscription auto-renewals, every repeat is clinically re-reviewed. We are not the cheapest option available. That is deliberate, because the things that make treatment safe (identity checks, live weight verification on video, a prescriber who reads your answers personally) cost time and resource, and we would rather be honest about that than strip them out to compete on price. If you want to see exactly what is included at each dose, our Wegovy bundle price page breaks down the full cost clearly. You can see exactly what treatment costs on our treatments page.
Wegovy is a Prescription-Only Medicine. The MHRA has warned publicly about counterfeit weight-loss pens circulating online and via social media, some containing insulin rather than semaglutide. Sellers offering these medicines without a prescription, at prices far below the market, or with discount codes from unverified accounts are a recognised red flag. The safe route is a prescription issued by a qualified prescriber, dispensed by a pharmacy you can check on the GPhC register.
For a medicine that works by titrating carefully over months, clinical continuity matters too. Knowing that a prescriber will review your progress, check your weight evidence before each repeat, and be reachable seven days a week if something feels off, that is part of what the price of a properly run service reflects. A small saving on the pen itself is not the measure that keeps you safe or supported through a year-long treatment course.
Our Wegovy overview covers eligibility, the titration schedule, and what to expect at each stage. If you would like to understand how Wegovy compares across different expected outcomes, this page covers the full picture. When you are ready to take the next step, our prescribers review consultations the same day, you can check your eligibility here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.